世界の調剤薬局市場規模調査および予測:製品別(経口、外用、非経口)、調剤タイプ別(成分変更、投与量変更)、治療用途別(疼痛管理、ホルモン補充療法)、無菌性別(無菌)、エンドユーザー別(小児、成人)、および地域別予測(2025年~2035年)Global Compounding Pharmacy Market Size Study and Forecast by Product (Oral, Topical, Parenteral), Compounding Type (Ingredient Alteration, Dosage Alteration), Therapeutic Application (Pain Management, HRT), Sterility (Sterile), and End User (Pediatric, Adult), and Regional Forecasts 20252035 Market Definition, Recent Developments & Industry Trends The compounding pharmacy market encompasses the customized preparation of medications tailored to the specific needs of individual patients... もっと見る
出版社
Bizwit Research & Consulting LLP
ビズウィットリサーチ&コンサルティング 出版年月
2026年3月24日
電子版価格
納期
3-5営業日以内
ページ数
285
言語
英語
英語原文をAI翻訳して掲載しています。
サマリーMarket Definition, Recent Developments & Industry TrendsThe compounding pharmacy market encompasses the customized preparation of medications tailored to the specific needs of individual patients when commercially available drugs are unsuitable. Compounding pharmacies formulate personalized medications by altering dosage strength, combining active ingredients, removing allergens, or modifying dosage forms. The ecosystem comprises independent and hospital-based compounding pharmacies, outsourcing facilities, raw material suppliers, regulatory bodies, and healthcare providers prescribing customized formulations across multiple therapeutic areas. In recent years, the market has evolved from a largely fragmented, community-based practice to a more regulated and quality-focused industry segment. Heightened regulatory oversight, particularly for sterile compounding, has led to increased compliance investments and operational standardization. Concurrently, growing demand for personalized medicine, hormone replacement therapy (HRT), pediatric formulations, and pain management solutions has expanded the commercial scope of compounding pharmacies. Technology integration in prescription management, quality control systems, and supply chain traceability is further reshaping the industry landscape. Over the forecast period 2025-2035, the market is expected to demonstrate steady growth, supported by demographic shifts, chronic disease prevalence, and the expanding acceptance of individualized therapeutic regimens. Key Findings of the Report - Market Size (2024): USD 13.93 billion - Estimated Market Size (2035): USD 25.63 billion - CAGR (2025-2035): 5.70% - Leading Regional Market: North America - Leading Segment: Oral formulations under Product segment Market Determinants Rising Demand for Personalized Therapeutics The increasing emphasis on patient-centric care models is a primary growth driver. Standardized, mass-produced medications often fail to address specific patient needs such as allergies, dosage sensitivity, or multi-drug compatibility. Compounding pharmacies offer individualized formulations, creating strong value propositions for healthcare providers seeking optimized therapeutic outcomes. This trend directly enhances prescription volumes and long-term customer retention. Growth in Chronic Pain and Hormone-Related Conditions The rising incidence of chronic pain disorders and age-related hormonal imbalances is expanding demand for customized pain management and HRT solutions. Patients requiring alternative dosages or delivery formats often rely on compounded medications, reinforcing steady demand within specialized therapeutic segments. As aging populations grow globally, this structural demand driver is expected to sustain long-term market expansion. Regulatory Evolution and Compliance Standards Increased regulatory scrutiny, particularly around sterile compounding practices, has reshaped operational frameworks. While stricter compliance raises costs and entry barriers, it also enhances credibility, improves patient safety, and fosters consolidation among established players. High compliance standards create competitive differentiation and reduce risks associated with quality lapses, strengthening institutional trust in compounding services. Supply Chain Vulnerabilities and Drug Shortages Frequent drug shortages in commercial pharmaceutical markets have elevated the importance of compounding pharmacies as alternative suppliers. Ingredient alteration and dosage modification capabilities allow rapid response to unavailable formulations. However, dependency on active pharmaceutical ingredient (API) sourcing and fluctuating raw material prices can constrain margins and operational scalability. Operational Complexity and Liability Risks Compounding activities, particularly sterile preparations, involve high procedural complexity and stringent quality control requirements. Liability exposure, recall risks, and compliance costs pose challenges to smaller operators. These constraints may limit expansion capacity but also incentivize consolidation and investment in automation and quality management systems. Opportunity Mapping Based on Market Trends Expansion in Sterile Compounding Capabilities Sterile compounding presents significant growth potential as healthcare institutions increasingly outsource complex injectable preparations. - Investment in advanced cleanroom infrastructure - Adoption of automated sterile filling systems - Partnerships with hospital networks These initiatives position providers to capture higher-margin institutional contracts and reduce contamination risks. Specialty Therapeutic Customization Targeted growth in pain management and HRT reflects broader personalization trends. - Development of niche formulations - Integration of digital prescription platforms - Enhanced collaboration with specialty clinics Such specialization enables differentiation in a competitive landscape and supports premium pricing strategies. Pediatric and Geriatric Formulation Innovation Demographic shifts are creating demand for age-appropriate dosage forms. - Flavor-masked oral suspensions - Adjusted-dose capsules - Non-invasive topical applications Companies investing in patient-friendly delivery systems can strengthen loyalty among pediatric and geriatric segments. Technology-Driven Quality and Traceability Digital quality assurance systems and electronic documentation enhance regulatory compliance and operational efficiency. - Automated batch tracking - Data-driven compliance audits - Inventory optimization platforms Technology adoption not only reduces risk exposure but also supports scalable growth models. Key Market Segments By Product: - Oral - Topical - Parenteral By Compounding Type: - Ingredient Alteration - Dosage Alteration By Therapeutic Application: - Pain Management - HRT By Sterility: - Sterile By End User: - Pediatric - Adult Value-Creating Segments and Growth Pockets Oral formulations currently dominate the market due to their ease of administration, widespread therapeutic applicability, and cost efficiency. However, parenteral products-particularly sterile injectables-are expected to exhibit accelerated growth as hospital outsourcing increases and regulatory compliance standards strengthen. Within compounding types, dosage alteration remains foundational to everyday compounding activities, while ingredient alteration is gaining momentum due to allergy considerations and combination therapies. In therapeutic applications, pain management holds a substantial share driven by chronic conditions, whereas HRT is projected to grow steadily, supported by aging demographics and increased awareness. From an end-user perspective, adult patients represent the larger revenue base today, yet pediatric formulations are emerging as a high-growth pocket given the lack of commercially available child-specific dosages and delivery formats. Regional Market Assessment North America North America leads the global compounding pharmacy market, driven by advanced healthcare infrastructure, high chronic disease prevalence, and a well-established regulatory framework. Strong physician acceptance of personalized therapeutics and frequent drug shortages further reinforce regional dominance. Europe Europe demonstrates stable growth supported by aging populations and expanding HRT utilization. Regulatory harmonization efforts and increasing oversight of sterile compounding practices are shaping market structure, encouraging consolidation and quality standardization. Asia Pacific Asia Pacific is poised for accelerated growth due to expanding healthcare access, rising middle-class populations, and increasing awareness of personalized medicine. Cost-sensitive markets and local manufacturing capabilities create opportunities for scalable compounding services. LAMEA The LAMEA region is characterized by gradual adoption, driven by improving healthcare infrastructure and increasing demand for specialty formulations. Market growth remains uneven across countries but presents long-term opportunities as regulatory frameworks mature. Recent Developments - March 2024: Expansion of sterile compounding facilities by a leading outsourcing pharmacy group to increase hospital contract capacity, strengthening institutional supply reliability. - September 2023: Strategic partnership between a compounding pharmacy and a specialty pain clinic network to develop customized chronic pain formulations, enhancing therapeutic integration. - January 2023: Investment in automated quality control and cleanroom technology by a regional compounding provider, improving regulatory compliance and reducing contamination risk. Critical Business Questions Addressed - What is the projected value creation trajectory of the global compounding pharmacy market through 2035- The report quantifies revenue growth and identifies structural drivers underpinning the 5.70% CAGR outlook. - Which product and therapeutic segments will drive incremental revenue- Detailed segmentation analysis highlights oral dominance and the emerging potential of sterile parenteral and HRT applications. - How will regulatory evolution influence competitive positioning- The study evaluates compliance-driven consolidation and the strategic advantage of high-standard sterile facilities. - Where should stakeholders prioritize geographic expansion- Regional analysis identifies North America as mature and Asia Pacific as a high-growth opportunity zone. - What operational capabilities are critical for long-term competitiveness- Investment in technology, quality systems, and specialty therapeutic integration emerges as a strategic imperative. Beyond the Forecast The compounding pharmacy market is transitioning from a fragmented service niche to a strategically important extension of personalized healthcare delivery. Long-term growth will be defined by regulatory discipline, sterile infrastructure expansion, and therapeutic specialization. Market participants that combine compliance excellence with scalable, technology-enabled operations will be best positioned to capture sustained value in an increasingly patient-centric pharmaceutical ecosystem. 目次Table of ContentsChapter 1. Global Compounding Pharmacy Market Report Scope & Methodology 1.1. Market Definition 1.2. Market Segmentation 1.3. Research Assumption 1.3.1. Inclusion & Exclusion 1.3.2. Limitations 1.4. Research Objective 1.5. Research Methodology 1.5.1. Forecast Model 1.5.2. Desk Research 1.5.3. Top Down and Bottom-Up Approach 1.6. Research Attributes 1.7. Years Considered for the Study Chapter 2. Executive Summary 2.1. Market Snapshot 2.2. Strategic Insights 2.3. Top Findings 2.4. CEO/CXO Standpoint 2.5. ESG Analysis Chapter 3. Global Compounding Pharmacy Market Forces Analysis 3.1. Market Forces Shaping The Global Compounding Pharmacy Market (2024-2035) 3.2. Drivers 3.2.1. Rising Demand for Personalized Therapeutics 3.2.2. Growth in Chronic Pain and Hormone-Related Conditions 3.2.3. Regulatory Evolution and Compliance Standards 3.3. Restraints 3.3.1. Operational Complexity and Liability Risks 3.3.2. Supply Chain Vulnerabilities and Drug Shortages 3.4. Opportunities 3.4.1. Expansion in Sterile Compounding Capabilities 3.4.2. Specialty Therapeutic Customization Chapter 4. Global Compounding Pharmacy Industry Analysis 4.1. Porter’s 5 Forces Model 4.2. Porter’s 5 Force Forecast Model (2024-2035) 4.3. PESTEL Analysis 4.4. Macroeconomic Industry Trends 4.4.1. Parent Market Trends 4.4.2. GDP Trends & Forecasts 4.5. Value Chain Analysis 4.6. Top Investment Trends & Forecasts 4.7. Top Winning Strategies (2025) 4.8. Market Share Analysis (2024-2025) 4.9. Pricing Analysis 4.10. Investment & Funding Scenario 4.11. Impact of Geopolitical & Trade Policy Volatility on the Market Chapter 5. AI Adoption Trends and Market Influence 5.1. AI Readiness Index 5.2. Key Emerging Technologies 5.3. Patent Analysis 5.4. Top Case Studies Chapter 6. Global Compounding Pharmacy Market Size & Forecasts by Product 2025-2035 6.1. Market Overview 6.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025) 6.3. Oral 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.3.2. Market size analysis, by region, 2025-2035 6.4. Topical 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.4.2. Market size analysis, by region, 2025-2035 6.5. Parenteral 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.5.2. Market size analysis, by region, 2025-2035 Chapter 7. Global Compounding Pharmacy Market Size & Forecasts by Compounding Type 2025-2035 7.1. Market Overview 7.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025) 7.3. Ingredient Alteration 7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.3.2. Market size analysis, by region, 2025-2035 7.4. Dosage Alteration 7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.4.2. Market size analysis, by region, 2025-2035 Chapter 8. Global Compounding Pharmacy Market Size & Forecasts by Therapeutic Application 2025-2035 8.1. Market Overview 8.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025) 8.3. Pain Management 8.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.3.2. Market size analysis, by region, 2025-2035 8.4. HRT 8.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.4.2. Market size analysis, by region, 2025-2035 Chapter 9. Global Compounding Pharmacy Market Size & Forecasts by Sterility2025-2035 9.1. Market Overview 9.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025) 9.3. Sterile 9.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 9.3.2. Market size analysis, by region, 2025-2035 Chapter 10. Global Compounding Pharmacy Market Size & Forecasts by End User 10.1. Market Overview 10.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025) 10.3. Pediatirc 10.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.3.2. Market size analysis, by region, 2025-2035 10.4. Adult 10.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.4.2. Market size analysis, by region, 2025-2035 Chapter 11. Global Compounding Pharmacy Market Size & Forecasts by Region 2025–2035 11.1. Growth Compounding Pharmacy Market, Regional Market Snapshot 11.2. Top Leading & Emerging Countries 11.3. North America Compounding Pharmacy Market 11.3.1. U.S. Compounding Pharmacy Market 11.3.1.1. Product breakdown size & forecasts, 2025-2035 11.3.1.2. Compounding Type breakdown size & forecasts, 2025-2035 11.3.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.3.1.4. Sterility breakdown size & forecasts, 2025-2035 11.3.1.5. End User breakdown size & forecasts, 2025-2035 11.3.2. Canada Compounding Pharmacy Market 11.3.2.1. Product breakdown size & forecasts, 2025-2035 11.3.2.2. Compounding Type breakdown size & forecasts, 2025-2035 11.3.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.3.2.4. Sterility breakdown size & forecasts, 2025-2035 11.3.2.5. End User breakdown size & forecasts, 2025-2035 11.4. Europe Compounding Pharmacy Market 11.4.1. UK Compounding Pharmacy Market 11.4.1.1. Product breakdown size & forecasts, 2025-2035 11.4.1.2. Compounding Type breakdown size & forecasts, 2025-2035 11.4.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.4.1.4. Sterility breakdown size & forecasts, 2025-2035 11.4.1.5. End User breakdown size & forecasts, 2025-2035 11.4.2. Germany Compounding Pharmacy Market 11.4.2.1. Product breakdown size & forecasts, 2025-2035 11.4.2.2. Compounding Type breakdown size & forecasts, 2025-2035 11.4.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.4.2.4. Sterility breakdown size & forecasts, 2025-2035 11.4.2.5. End User breakdown size & forecasts, 2025-2035 11.4.3. France Compounding Pharmacy Market 11.4.3.1. Product breakdown size & forecasts, 2025-2035 11.4.3.2. Compounding Type breakdown size & forecasts, 2025-2035 11.4.3.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.4.3.4. Sterility breakdown size & forecasts, 2025-2035 11.4.3.5. End User breakdown size & forecasts, 2025-2035 11.4.4. Spain Compounding Pharmacy Market 11.4.4.1. Product breakdown size & forecasts, 2025-2035 11.4.4.2. Compounding Type breakdown size & forecasts, 2025-2035 11.4.4.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.4.4.4. Sterility breakdown size & forecasts, 2025-2035 11.4.4.5. End User breakdown size & forecasts, 2025-2035 11.4.5. Italy Compounding Pharmacy Market 11.4.5.1. Product breakdown size & forecasts, 2025-2035 11.4.5.2. Compounding Type breakdown size & forecasts, 2025-2035 11.4.5.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.4.5.4. Sterility breakdown size & forecasts, 2025-2035 11.4.5.5. End User breakdown size & forecasts, 2025-2035 11.4.6. Rest of Europe Compounding Pharmacy Market 11.4.6.1. Product breakdown size & forecasts, 2025-2035 11.4.6.2. Compounding Type breakdown size & forecasts, 2025-2035 11.4.6.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.4.6.4. Sterility breakdown size & forecasts, 2025-2035 11.4.6.5. End User breakdown size & forecasts, 2025-2035 11.5. Asia Pacific Compounding Pharmacy Market 11.5.1. China Compounding Pharmacy Market 11.5.1.1. Product breakdown size & forecasts, 2025-2035 11.5.1.2. Compounding Type breakdown size & forecasts, 2025-2035 11.5.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.5.1.4. Sterility breakdown size & forecasts, 2025-2035 11.5.1.5. End User breakdown size & forecasts, 2025-2035 11.5.2. India Compounding Pharmacy Market 11.5.2.1. Product breakdown size & forecasts, 2025-2035 11.5.2.2. Compounding Type breakdown size & forecasts, 2025-2035 11.5.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.5.2.4. Sterility breakdown size & forecasts, 2025-2035 11.5.2.5. End User breakdown size & forecasts, 2025-2035 11.5.3. Japan Compounding Pharmacy Market 11.5.3.1. Product breakdown size & forecasts, 2025-2035 11.5.3.2. Compounding Type breakdown size & forecasts, 2025-2035 11.5.3.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.5.3.4. Sterility breakdown size & forecasts, 2025-2035 11.5.3.5. End User breakdown size & forecasts, 2025-2035 11.5.4. Australia Compounding Pharmacy Market 11.5.4.1. Product breakdown size & forecasts, 2025-2035 11.5.4.2. Compounding Type breakdown size & forecasts, 2025-2035 11.5.4.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.5.4.4. Sterility breakdown size & forecasts, 2025-2035 11.5.4.5. End User breakdown size & forecasts, 2025-2035 11.5.5. South Korea Compounding Pharmacy Market 11.5.5.1. Product breakdown size & forecasts, 2025-2035 11.5.5.2. Compounding Type breakdown size & forecasts, 2025-2035 11.5.5.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.5.5.4. Sterility breakdown size & forecasts, 2025-2035 11.5.5.5. End User breakdown size & forecasts, 2025-2035 11.5.6. Rest of APAC Compounding Pharmacy Market 11.5.6.1. Product breakdown size & forecasts, 2025-2035 11.5.6.2. Compounding Type breakdown size & forecasts, 2025-2035 11.5.6.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.5.6.4. Sterility breakdown size & forecasts, 2025-2035 11.5.6.5. End User breakdown size & forecasts, 2025-2035 11.6. Latin America Compounding Pharmacy Market 11.6.1. Brazil Compounding Pharmacy Market 11.6.1.1. Product breakdown size & forecasts, 2025-2035 11.6.1.2. Compounding Type breakdown size & forecasts, 2025-2035 11.6.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.6.1.4. Sterility breakdown size & forecasts, 2025-2035 11.6.1.5. End User breakdown size & forecasts, 2025-2035 11.6.2. Mexico Compounding Pharmacy Market 11.6.2.1. Product breakdown size & forecasts, 2025-2035 11.6.2.2. Compounding Type breakdown size & forecasts, 2025-2035 11.6.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.6.2.4. Sterility breakdown size & forecasts, 2025-2035 11.6.2.5. End User breakdown size & forecasts, 2025-2035 11.7. Middle East and Africa Compounding Pharmacy Market 11.7.1. UAE Compounding Pharmacy Market 11.7.1.1. Product breakdown size & forecasts, 2025-2035 11.7.1.2. Compounding Type breakdown size & forecasts, 2025-2035 11.7.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.7.1.4. Sterility breakdown size & forecasts, 2025-2035 11.7.1.5. End User breakdown size & forecasts, 2025-2035 11.7.2. Saudi Arabia (KSA) Compounding Pharmacy Market 11.7.2.1. Product breakdown size & forecasts, 2025-2035 11.7.2.2. Compounding Type breakdown size & forecasts, 2025-2035 11.7.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.7.2.4. Sterility breakdown size & forecasts, 2025-2035 11.7.2.5. End User breakdown size & forecasts, 2025-2035 11.7.3. South Africa Compounding Pharmacy Market 11.7.3.1. Product breakdown size & forecasts, 2025-2035 11.7.3.2. Compounding Type breakdown size & forecasts, 2025-2035 11.7.3.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.7.3.4. Sterility breakdown size & forecasts, 2025-2035 11.7.3.5. End User breakdown size & forecasts, 2025-2035 Chapter 12. Competitive Intelligence 12.1. Top Market Strategies 12.2. Walgreen Co. 12.2.1. Company Overview 12.2.2. Key Executives 12.2.3. Company Snapshot 12.2.4. Financial Performance (Subject to Data Availability) 12.2.5. Product/Services Port 12.2.6. Recent Development 12.2.7. Market Strategies 12.2.8. SWOT Analysis 12.3. JL Diekman and AQ Touchard (Fresh Therapeutics Compounding Pharmacy) 12.4. Fagron 12.5. Albertsons Companies 12.6. The London Specialist Pharmacy Ltd (Specialist Pharmacy) 12.7. Galenic Laboratories Limited (Roseway Labs) 12.8. Aurora Compounding 12.9. MEDS Pharmacy 12.10. Apollo Clinical Pharmacy 12.11. Formul8 12.12. Fusion Apothecary 図表リストList of TablesTable 1. Global Compounding Pharmacy Market, Report Scope Table 2. Global Compounding Pharmacy Market Estimates & Forecasts By Region 2024–2035 Table 3. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035 Table 4. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035 Table 5. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035 Table 6. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035 Table 7. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035 Table 8. U.S. Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 9. Canada Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 10. UK Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 11. Germany Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 12. France Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 13. Spain Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 14. Italy Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 15. Rest Of Europe Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 16. China Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 17. India Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 18. Japan Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 19. Australia Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 20. South Korea Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 ………….
SummaryMarket Definition, Recent Developments & Industry TrendsThe compounding pharmacy market encompasses the customized preparation of medications tailored to the specific needs of individual patients when commercially available drugs are unsuitable. Compounding pharmacies formulate personalized medications by altering dosage strength, combining active ingredients, removing allergens, or modifying dosage forms. The ecosystem comprises independent and hospital-based compounding pharmacies, outsourcing facilities, raw material suppliers, regulatory bodies, and healthcare providers prescribing customized formulations across multiple therapeutic areas. In recent years, the market has evolved from a largely fragmented, community-based practice to a more regulated and quality-focused industry segment. Heightened regulatory oversight, particularly for sterile compounding, has led to increased compliance investments and operational standardization. Concurrently, growing demand for personalized medicine, hormone replacement therapy (HRT), pediatric formulations, and pain management solutions has expanded the commercial scope of compounding pharmacies. Technology integration in prescription management, quality control systems, and supply chain traceability is further reshaping the industry landscape. Over the forecast period 2025-2035, the market is expected to demonstrate steady growth, supported by demographic shifts, chronic disease prevalence, and the expanding acceptance of individualized therapeutic regimens. Key Findings of the Report - Market Size (2024): USD 13.93 billion - Estimated Market Size (2035): USD 25.63 billion - CAGR (2025-2035): 5.70% - Leading Regional Market: North America - Leading Segment: Oral formulations under Product segment Market Determinants Rising Demand for Personalized Therapeutics The increasing emphasis on patient-centric care models is a primary growth driver. Standardized, mass-produced medications often fail to address specific patient needs such as allergies, dosage sensitivity, or multi-drug compatibility. Compounding pharmacies offer individualized formulations, creating strong value propositions for healthcare providers seeking optimized therapeutic outcomes. This trend directly enhances prescription volumes and long-term customer retention. Growth in Chronic Pain and Hormone-Related Conditions The rising incidence of chronic pain disorders and age-related hormonal imbalances is expanding demand for customized pain management and HRT solutions. Patients requiring alternative dosages or delivery formats often rely on compounded medications, reinforcing steady demand within specialized therapeutic segments. As aging populations grow globally, this structural demand driver is expected to sustain long-term market expansion. Regulatory Evolution and Compliance Standards Increased regulatory scrutiny, particularly around sterile compounding practices, has reshaped operational frameworks. While stricter compliance raises costs and entry barriers, it also enhances credibility, improves patient safety, and fosters consolidation among established players. High compliance standards create competitive differentiation and reduce risks associated with quality lapses, strengthening institutional trust in compounding services. Supply Chain Vulnerabilities and Drug Shortages Frequent drug shortages in commercial pharmaceutical markets have elevated the importance of compounding pharmacies as alternative suppliers. Ingredient alteration and dosage modification capabilities allow rapid response to unavailable formulations. However, dependency on active pharmaceutical ingredient (API) sourcing and fluctuating raw material prices can constrain margins and operational scalability. Operational Complexity and Liability Risks Compounding activities, particularly sterile preparations, involve high procedural complexity and stringent quality control requirements. Liability exposure, recall risks, and compliance costs pose challenges to smaller operators. These constraints may limit expansion capacity but also incentivize consolidation and investment in automation and quality management systems. Opportunity Mapping Based on Market Trends Expansion in Sterile Compounding Capabilities Sterile compounding presents significant growth potential as healthcare institutions increasingly outsource complex injectable preparations. - Investment in advanced cleanroom infrastructure - Adoption of automated sterile filling systems - Partnerships with hospital networks These initiatives position providers to capture higher-margin institutional contracts and reduce contamination risks. Specialty Therapeutic Customization Targeted growth in pain management and HRT reflects broader personalization trends. - Development of niche formulations - Integration of digital prescription platforms - Enhanced collaboration with specialty clinics Such specialization enables differentiation in a competitive landscape and supports premium pricing strategies. Pediatric and Geriatric Formulation Innovation Demographic shifts are creating demand for age-appropriate dosage forms. - Flavor-masked oral suspensions - Adjusted-dose capsules - Non-invasive topical applications Companies investing in patient-friendly delivery systems can strengthen loyalty among pediatric and geriatric segments. Technology-Driven Quality and Traceability Digital quality assurance systems and electronic documentation enhance regulatory compliance and operational efficiency. - Automated batch tracking - Data-driven compliance audits - Inventory optimization platforms Technology adoption not only reduces risk exposure but also supports scalable growth models. Key Market Segments By Product: - Oral - Topical - Parenteral By Compounding Type: - Ingredient Alteration - Dosage Alteration By Therapeutic Application: - Pain Management - HRT By Sterility: - Sterile By End User: - Pediatric - Adult Value-Creating Segments and Growth Pockets Oral formulations currently dominate the market due to their ease of administration, widespread therapeutic applicability, and cost efficiency. However, parenteral products-particularly sterile injectables-are expected to exhibit accelerated growth as hospital outsourcing increases and regulatory compliance standards strengthen. Within compounding types, dosage alteration remains foundational to everyday compounding activities, while ingredient alteration is gaining momentum due to allergy considerations and combination therapies. In therapeutic applications, pain management holds a substantial share driven by chronic conditions, whereas HRT is projected to grow steadily, supported by aging demographics and increased awareness. From an end-user perspective, adult patients represent the larger revenue base today, yet pediatric formulations are emerging as a high-growth pocket given the lack of commercially available child-specific dosages and delivery formats. Regional Market Assessment North America North America leads the global compounding pharmacy market, driven by advanced healthcare infrastructure, high chronic disease prevalence, and a well-established regulatory framework. Strong physician acceptance of personalized therapeutics and frequent drug shortages further reinforce regional dominance. Europe Europe demonstrates stable growth supported by aging populations and expanding HRT utilization. Regulatory harmonization efforts and increasing oversight of sterile compounding practices are shaping market structure, encouraging consolidation and quality standardization. Asia Pacific Asia Pacific is poised for accelerated growth due to expanding healthcare access, rising middle-class populations, and increasing awareness of personalized medicine. Cost-sensitive markets and local manufacturing capabilities create opportunities for scalable compounding services. LAMEA The LAMEA region is characterized by gradual adoption, driven by improving healthcare infrastructure and increasing demand for specialty formulations. Market growth remains uneven across countries but presents long-term opportunities as regulatory frameworks mature. Recent Developments - March 2024: Expansion of sterile compounding facilities by a leading outsourcing pharmacy group to increase hospital contract capacity, strengthening institutional supply reliability. - September 2023: Strategic partnership between a compounding pharmacy and a specialty pain clinic network to develop customized chronic pain formulations, enhancing therapeutic integration. - January 2023: Investment in automated quality control and cleanroom technology by a regional compounding provider, improving regulatory compliance and reducing contamination risk. Critical Business Questions Addressed - What is the projected value creation trajectory of the global compounding pharmacy market through 2035- The report quantifies revenue growth and identifies structural drivers underpinning the 5.70% CAGR outlook. - Which product and therapeutic segments will drive incremental revenue- Detailed segmentation analysis highlights oral dominance and the emerging potential of sterile parenteral and HRT applications. - How will regulatory evolution influence competitive positioning- The study evaluates compliance-driven consolidation and the strategic advantage of high-standard sterile facilities. - Where should stakeholders prioritize geographic expansion- Regional analysis identifies North America as mature and Asia Pacific as a high-growth opportunity zone. - What operational capabilities are critical for long-term competitiveness- Investment in technology, quality systems, and specialty therapeutic integration emerges as a strategic imperative. Beyond the Forecast The compounding pharmacy market is transitioning from a fragmented service niche to a strategically important extension of personalized healthcare delivery. Long-term growth will be defined by regulatory discipline, sterile infrastructure expansion, and therapeutic specialization. Market participants that combine compliance excellence with scalable, technology-enabled operations will be best positioned to capture sustained value in an increasingly patient-centric pharmaceutical ecosystem. Table of ContentsTable of ContentsChapter 1. Global Compounding Pharmacy Market Report Scope & Methodology 1.1. Market Definition 1.2. Market Segmentation 1.3. Research Assumption 1.3.1. Inclusion & Exclusion 1.3.2. Limitations 1.4. Research Objective 1.5. Research Methodology 1.5.1. Forecast Model 1.5.2. Desk Research 1.5.3. Top Down and Bottom-Up Approach 1.6. Research Attributes 1.7. Years Considered for the Study Chapter 2. Executive Summary 2.1. Market Snapshot 2.2. Strategic Insights 2.3. Top Findings 2.4. CEO/CXO Standpoint 2.5. ESG Analysis Chapter 3. Global Compounding Pharmacy Market Forces Analysis 3.1. Market Forces Shaping The Global Compounding Pharmacy Market (2024-2035) 3.2. Drivers 3.2.1. Rising Demand for Personalized Therapeutics 3.2.2. Growth in Chronic Pain and Hormone-Related Conditions 3.2.3. Regulatory Evolution and Compliance Standards 3.3. Restraints 3.3.1. Operational Complexity and Liability Risks 3.3.2. Supply Chain Vulnerabilities and Drug Shortages 3.4. Opportunities 3.4.1. Expansion in Sterile Compounding Capabilities 3.4.2. Specialty Therapeutic Customization Chapter 4. Global Compounding Pharmacy Industry Analysis 4.1. Porter’s 5 Forces Model 4.2. Porter’s 5 Force Forecast Model (2024-2035) 4.3. PESTEL Analysis 4.4. Macroeconomic Industry Trends 4.4.1. Parent Market Trends 4.4.2. GDP Trends & Forecasts 4.5. Value Chain Analysis 4.6. Top Investment Trends & Forecasts 4.7. Top Winning Strategies (2025) 4.8. Market Share Analysis (2024-2025) 4.9. Pricing Analysis 4.10. Investment & Funding Scenario 4.11. Impact of Geopolitical & Trade Policy Volatility on the Market Chapter 5. AI Adoption Trends and Market Influence 5.1. AI Readiness Index 5.2. Key Emerging Technologies 5.3. Patent Analysis 5.4. Top Case Studies Chapter 6. Global Compounding Pharmacy Market Size & Forecasts by Product 2025-2035 6.1. Market Overview 6.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025) 6.3. Oral 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.3.2. Market size analysis, by region, 2025-2035 6.4. Topical 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.4.2. Market size analysis, by region, 2025-2035 6.5. Parenteral 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.5.2. Market size analysis, by region, 2025-2035 Chapter 7. Global Compounding Pharmacy Market Size & Forecasts by Compounding Type 2025-2035 7.1. Market Overview 7.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025) 7.3. Ingredient Alteration 7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.3.2. Market size analysis, by region, 2025-2035 7.4. Dosage Alteration 7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.4.2. Market size analysis, by region, 2025-2035 Chapter 8. Global Compounding Pharmacy Market Size & Forecasts by Therapeutic Application 2025-2035 8.1. Market Overview 8.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025) 8.3. Pain Management 8.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.3.2. Market size analysis, by region, 2025-2035 8.4. HRT 8.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.4.2. Market size analysis, by region, 2025-2035 Chapter 9. Global Compounding Pharmacy Market Size & Forecasts by Sterility2025-2035 9.1. Market Overview 9.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025) 9.3. Sterile 9.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 9.3.2. Market size analysis, by region, 2025-2035 Chapter 10. Global Compounding Pharmacy Market Size & Forecasts by End User 10.1. Market Overview 10.2. Global Compounding Pharmacy Market Performance - Potential Analysis (2025) 10.3. Pediatirc 10.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.3.2. Market size analysis, by region, 2025-2035 10.4. Adult 10.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 10.4.2. Market size analysis, by region, 2025-2035 Chapter 11. Global Compounding Pharmacy Market Size & Forecasts by Region 2025–2035 11.1. Growth Compounding Pharmacy Market, Regional Market Snapshot 11.2. Top Leading & Emerging Countries 11.3. North America Compounding Pharmacy Market 11.3.1. U.S. Compounding Pharmacy Market 11.3.1.1. Product breakdown size & forecasts, 2025-2035 11.3.1.2. Compounding Type breakdown size & forecasts, 2025-2035 11.3.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.3.1.4. Sterility breakdown size & forecasts, 2025-2035 11.3.1.5. End User breakdown size & forecasts, 2025-2035 11.3.2. Canada Compounding Pharmacy Market 11.3.2.1. Product breakdown size & forecasts, 2025-2035 11.3.2.2. Compounding Type breakdown size & forecasts, 2025-2035 11.3.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.3.2.4. Sterility breakdown size & forecasts, 2025-2035 11.3.2.5. End User breakdown size & forecasts, 2025-2035 11.4. Europe Compounding Pharmacy Market 11.4.1. UK Compounding Pharmacy Market 11.4.1.1. Product breakdown size & forecasts, 2025-2035 11.4.1.2. Compounding Type breakdown size & forecasts, 2025-2035 11.4.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.4.1.4. Sterility breakdown size & forecasts, 2025-2035 11.4.1.5. End User breakdown size & forecasts, 2025-2035 11.4.2. Germany Compounding Pharmacy Market 11.4.2.1. Product breakdown size & forecasts, 2025-2035 11.4.2.2. Compounding Type breakdown size & forecasts, 2025-2035 11.4.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.4.2.4. Sterility breakdown size & forecasts, 2025-2035 11.4.2.5. End User breakdown size & forecasts, 2025-2035 11.4.3. France Compounding Pharmacy Market 11.4.3.1. Product breakdown size & forecasts, 2025-2035 11.4.3.2. Compounding Type breakdown size & forecasts, 2025-2035 11.4.3.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.4.3.4. Sterility breakdown size & forecasts, 2025-2035 11.4.3.5. End User breakdown size & forecasts, 2025-2035 11.4.4. Spain Compounding Pharmacy Market 11.4.4.1. Product breakdown size & forecasts, 2025-2035 11.4.4.2. Compounding Type breakdown size & forecasts, 2025-2035 11.4.4.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.4.4.4. Sterility breakdown size & forecasts, 2025-2035 11.4.4.5. End User breakdown size & forecasts, 2025-2035 11.4.5. Italy Compounding Pharmacy Market 11.4.5.1. Product breakdown size & forecasts, 2025-2035 11.4.5.2. Compounding Type breakdown size & forecasts, 2025-2035 11.4.5.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.4.5.4. Sterility breakdown size & forecasts, 2025-2035 11.4.5.5. End User breakdown size & forecasts, 2025-2035 11.4.6. Rest of Europe Compounding Pharmacy Market 11.4.6.1. Product breakdown size & forecasts, 2025-2035 11.4.6.2. Compounding Type breakdown size & forecasts, 2025-2035 11.4.6.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.4.6.4. Sterility breakdown size & forecasts, 2025-2035 11.4.6.5. End User breakdown size & forecasts, 2025-2035 11.5. Asia Pacific Compounding Pharmacy Market 11.5.1. China Compounding Pharmacy Market 11.5.1.1. Product breakdown size & forecasts, 2025-2035 11.5.1.2. Compounding Type breakdown size & forecasts, 2025-2035 11.5.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.5.1.4. Sterility breakdown size & forecasts, 2025-2035 11.5.1.5. End User breakdown size & forecasts, 2025-2035 11.5.2. India Compounding Pharmacy Market 11.5.2.1. Product breakdown size & forecasts, 2025-2035 11.5.2.2. Compounding Type breakdown size & forecasts, 2025-2035 11.5.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.5.2.4. Sterility breakdown size & forecasts, 2025-2035 11.5.2.5. End User breakdown size & forecasts, 2025-2035 11.5.3. Japan Compounding Pharmacy Market 11.5.3.1. Product breakdown size & forecasts, 2025-2035 11.5.3.2. Compounding Type breakdown size & forecasts, 2025-2035 11.5.3.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.5.3.4. Sterility breakdown size & forecasts, 2025-2035 11.5.3.5. End User breakdown size & forecasts, 2025-2035 11.5.4. Australia Compounding Pharmacy Market 11.5.4.1. Product breakdown size & forecasts, 2025-2035 11.5.4.2. Compounding Type breakdown size & forecasts, 2025-2035 11.5.4.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.5.4.4. Sterility breakdown size & forecasts, 2025-2035 11.5.4.5. End User breakdown size & forecasts, 2025-2035 11.5.5. South Korea Compounding Pharmacy Market 11.5.5.1. Product breakdown size & forecasts, 2025-2035 11.5.5.2. Compounding Type breakdown size & forecasts, 2025-2035 11.5.5.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.5.5.4. Sterility breakdown size & forecasts, 2025-2035 11.5.5.5. End User breakdown size & forecasts, 2025-2035 11.5.6. Rest of APAC Compounding Pharmacy Market 11.5.6.1. Product breakdown size & forecasts, 2025-2035 11.5.6.2. Compounding Type breakdown size & forecasts, 2025-2035 11.5.6.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.5.6.4. Sterility breakdown size & forecasts, 2025-2035 11.5.6.5. End User breakdown size & forecasts, 2025-2035 11.6. Latin America Compounding Pharmacy Market 11.6.1. Brazil Compounding Pharmacy Market 11.6.1.1. Product breakdown size & forecasts, 2025-2035 11.6.1.2. Compounding Type breakdown size & forecasts, 2025-2035 11.6.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.6.1.4. Sterility breakdown size & forecasts, 2025-2035 11.6.1.5. End User breakdown size & forecasts, 2025-2035 11.6.2. Mexico Compounding Pharmacy Market 11.6.2.1. Product breakdown size & forecasts, 2025-2035 11.6.2.2. Compounding Type breakdown size & forecasts, 2025-2035 11.6.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.6.2.4. Sterility breakdown size & forecasts, 2025-2035 11.6.2.5. End User breakdown size & forecasts, 2025-2035 11.7. Middle East and Africa Compounding Pharmacy Market 11.7.1. UAE Compounding Pharmacy Market 11.7.1.1. Product breakdown size & forecasts, 2025-2035 11.7.1.2. Compounding Type breakdown size & forecasts, 2025-2035 11.7.1.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.7.1.4. Sterility breakdown size & forecasts, 2025-2035 11.7.1.5. End User breakdown size & forecasts, 2025-2035 11.7.2. Saudi Arabia (KSA) Compounding Pharmacy Market 11.7.2.1. Product breakdown size & forecasts, 2025-2035 11.7.2.2. Compounding Type breakdown size & forecasts, 2025-2035 11.7.2.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.7.2.4. Sterility breakdown size & forecasts, 2025-2035 11.7.2.5. End User breakdown size & forecasts, 2025-2035 11.7.3. South Africa Compounding Pharmacy Market 11.7.3.1. Product breakdown size & forecasts, 2025-2035 11.7.3.2. Compounding Type breakdown size & forecasts, 2025-2035 11.7.3.3. Therapeutic Application breakdown size & forecasts, 2025-2035 11.7.3.4. Sterility breakdown size & forecasts, 2025-2035 11.7.3.5. End User breakdown size & forecasts, 2025-2035 Chapter 12. Competitive Intelligence 12.1. Top Market Strategies 12.2. Walgreen Co. 12.2.1. Company Overview 12.2.2. Key Executives 12.2.3. Company Snapshot 12.2.4. Financial Performance (Subject to Data Availability) 12.2.5. Product/Services Port 12.2.6. Recent Development 12.2.7. Market Strategies 12.2.8. SWOT Analysis 12.3. JL Diekman and AQ Touchard (Fresh Therapeutics Compounding Pharmacy) 12.4. Fagron 12.5. Albertsons Companies 12.6. The London Specialist Pharmacy Ltd (Specialist Pharmacy) 12.7. Galenic Laboratories Limited (Roseway Labs) 12.8. Aurora Compounding 12.9. MEDS Pharmacy 12.10. Apollo Clinical Pharmacy 12.11. Formul8 12.12. Fusion Apothecary List of Tables/GraphsList of TablesTable 1. Global Compounding Pharmacy Market, Report Scope Table 2. Global Compounding Pharmacy Market Estimates & Forecasts By Region 2024–2035 Table 3. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035 Table 4. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035 Table 5. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035 Table 6. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035 Table 7. Global Compounding Pharmacy Market Estimates & Forecasts By Segment 2024–2035 Table 8. U.S. Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 9. Canada Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 10. UK Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 11. Germany Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 12. France Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 13. Spain Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 14. Italy Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 15. Rest Of Europe Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 16. China Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 17. India Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 18. Japan Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 19. Australia Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 Table 20. South Korea Compounding Pharmacy Market Estimates & Forecasts, 2024–2035 ………….
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
Bizwit Research & Consulting LLP社の 医療・ライフサイエンス分野 での最新刊レポート
本レポートと同じKEY WORD(pharmacy)の最新刊レポート
よくあるご質問Bizwit Research & Consulting LLP社はどのような調査会社ですか?Bizwit Research & Consulting (Bizwit Research & Consulting LLP)は世界の多様なマクロおよびマイクロ経済の動向を継続的に調査しています。 ... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|